The EMA has given the ‘yes’ to mavacamten, the first drug for hypertrophic cardiomyopathy, which affects 1 in 500 people and is the leading cause of sudden death in young people.
Treatment with myosin inhibitors requires periodic monitoring of the patient with echocardiography. Photo: SHUTTERSTOCK
Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.
